secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVADEL PHARMACEUTICALS PLC (—)
CIK:        0001012477
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001104659-24-058415
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avadel reports Q1 LUMRYZ revenue $27.2M; patient starts up 70%; pediatric sNDA accepted
--------------------------------------------------------------------------------

- Q1 2024 net product revenue of $27.2M from LUMRYZ; gross profit $25.7M.
- Net loss narrowed to $27.3M ($0.30 per share) vs. $30.8M ($0.48) in Q1 2023.
- Over 1,700 patients initiated therapy (up >70% from Dec 31); RYZUP enrollments 2,800 (up ~50%).
- FDA accepted sNDA for LUMRYZ in pediatric narcolepsy; PDUFA date set for Sept 7, 2024.
- On track to enroll first patient in Phase 3 idiopathic hypersomnia trial in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1012477/000110465924058415/0001104659-24-058415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1012477/000110465924058415/tm2413641d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-058415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer